Go Pro
→ Feds Say Your Cash Isn’t Property—Can They Take It? (From Priority Gold) (Ad)tc pixel Free ATTO Stock Alerts

Attovia Therapeutics (ATTO) Stock Forecast & Price Target

$23.44 +0.65 (+2.85%)
As of 11:19 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Attovia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings
Sell
0
Hold
1
Buy
5

Based on 6 Wall Street analysts who have issued ratings for Attovia Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for ATTO.

Consensus Price Target

$42.20
80.03% Upside
According to the 6 analysts' twelve-month price targets for Attovia Therapeutics, the average price target is $42.20. The highest price target for ATTO is $52.00, while the lowest price target for ATTO is $30.00. The average price target represents a forecasted upside of 80.03% from the current price of $23.44.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ATTO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Attovia Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATTO Analyst Ratings Over Time

TypeCurrent Forecast
9/14/25 to 9/14/26		1 Month Ago
8/15/25 to 8/15/26		3 Months Ago
6/16/25 to 6/16/26		1 Year Ago
9/14/24 to 9/14/25
Strong Buy
0 Strong Buy rating(s)
 N/A N/A N/A
Buy
5 Buy rating(s)
 N/A N/A N/A
Hold
1 Hold rating(s)
 N/A N/A N/A
Sell
0 Sell rating(s)
 N/A N/A N/A
Consensus Price Target$42.20N/AN/AN/A
Forecasted Upside80.03% UpsideN/AN/AN/A
Consensus RatingModerate BuyN/AN/AN/A

ATTO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATTO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Attovia Therapeutics Stock vs. The Competition

TypeAttovia Therapeutics CompaniesBroader Market
Consensus Rating Score
2.83
1.70
2.53
Consensus RatingModerate BuyReduceModerate Buy
Predicted Upside85.17% Upside152.57% Upside16.41% Upside
News Sentiment Rating
Very Positive News

See Recent ATTO News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/4/2026
Zacks Research logo
Zacks Research
5 of 5 stars
 UpgradeHold
8/31/2026
Lifesci Capital logo
Lifesci Capital
5 of 5 stars
 Initiated CoverageOutperform$45.00+122.90%
8/31/2026
Royal Bank Of Canada logo
Royal Bank Of Canada
3 of 5 stars
Brian Abrahams
Brian Abrahams
4 of 5 stars
Initiated CoverageOutperform$45.00+117.39%
8/31/2026
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Yigal Nochomovitz
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageBuy$30.00+44.93%
8/31/2026
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Thomas Smith
Thomas Smith
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageOutperform$52.00+151.21%
8/31/2026
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Judah Frommer
Judah Frommer
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageOverweight$39.00+88.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:19 AM ET.


ATTO Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Attovia Therapeutics is $42.20, with a high forecast of $52.00 and a low forecast of $30.00.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Attovia Therapeutics in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATTO shares.

According to analysts, Attovia Therapeutics's stock has a predicted upside of 80.03% based on their 12-month stock forecasts.

Over the previous 90 days, Attovia Therapeutics's stock had 2 upgrades by analysts.

Attovia Therapeutics has been rated by research analysts at Citigroup, Leerink Partners, Lifesci Capital, Morgan Stanley, Royal Bank Of Canada, and Zacks Research in the past 90 days.

Analysts like Attovia Therapeutics more than other "" companies. The consensus rating for Attovia Therapeutics is Moderate Buy while the average consensus rating for "" companies is Reduce. Learn more on how ATTO compares to other companies.

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Attovia Therapeutics Recommendations


MarketBeat monitors more than a dozen sources for Attovia Therapeutics analyst ratings, with the most recent rating issued on 9/4/2026.
From Our Partners
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
Gold just passed our debt as the world's #1 asset
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
Print this before your next trade
Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...
Profits Run | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
What is Elon Building in Texas?
Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...
InvestorPlace | Sponsoredtc pixel